Corporate Profile

Overview

Founded April 16, 1913
Incorporated April 28, 1945
Paid-In Capital ¥7.2 billion; listed on the First Section of the Tokyo Stock Exchange
Employees 1,558(Consolidated)※As of March 2021
Head Office 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo 162-0845, Japan
Tel +81-3-3358-7211
Fax +81-3-3358-7887

Members of the Board

As of June 29, 2021
Representative Director, President Naoyuki Mochida
Representative Director, Senior Executive Vice President Chu Sakata
Member of the Board, Senior Executive Managing Officer Keiichi Sagisaka
Junichi Sakaki, Ph.D.
Member of the Board, Executive Managing Officer Kiyoshi Mizuguchi, Ph.D.
Member of the Board, Executive Officer Yutaka Kawakami, Ph.D.
Yoshiharu Hashimoto
Outside Director Tomoo Kugisawa
Hirokuni Sogawa
Nana Otsuki

Audit & Supervisory Board Members

As of June 29, 2021
Full-Time Audit & Supervisory Board Member Ichiro Takahashi
Kazuhiro Miyaji
Outside Audit & Supervisory Board Member Kyosuke Wagai
Akiko Suzuki
Yoshifumi Miyata

Executive Officers

As of June 29, 2021
Executive Officer Masaaki Naotsuka
Kazumasa Fukuchi
Tomokazu Matsusue
Hitoshi Mizuno
Taiji Hayano
Kazunari Nakao
Takeshi Mochida
Yoshitaka Hosaka, Ph.D.
Kenji Miyajima
Masayoshi Takeda
Reiko Nakano
Junichi Makino

Consolidated Financial Highlights

Years ended March 31
  Millions of Yen
2022
(forecast)
2021 2020
Net sales 101,500 102,995 101,799
Operating income 8,000 12,003 8,807
Income before income taxes
and minority interests
11,900 6,273
Income taxes 3,312*1 1,675*1
Net income 6,000 8,587 4,598
Total assets 161,791 157,488
R&D expenditures 13,500 10,849 11,884
Capital expenditures 1,600 1,335 1,889
  Yen
Net income per share 156.8 222.3 117.6
Cash dividends per share 80.0 90.0 80.0
  • *1 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \3,144 million), income taxes-deferred(\168 million)is included.
  • *2 As a result of tax effect accounting, corporate tax, resident tax and business tax (total \2,349 million), income taxes-deferred(-\674 million)is included.

Sales of Main Products

Years ended March 31
  Billions of Yen
Products 2022
(forecast)
2021 2020
Lexapro® Antidepressant 14.7 15.5 16.5
Lialda® Treatment of ulcerative colitis 11.2 10.9 9.0
Epadel Drug for hyperlipidemia and arteriosclerosis obliterans 8.3 10.1 12.1
Goofice® Treatment for chronic constipation 6.6 4.9 3.7
Tramcet® Analgesic for chronic pain and pain after tooth extraction 3.1 4.2 7.1
Atelec® Calcium channel blocker with a long-acting hypotensive effect 2.7 3.9 4.5
Movicol® Treatment for chronic constipation 3.8 3.5 1.8
Doxil® Anticancer agent 2.6 3.0 2.8
Dinagest Therapeutic agent for endometriosis, adenomyosis and dysmenorrhea 2.0 2.2 1.6
Treprost® Treatment for pulmonary arterial hypertension 1.7 1.6 1.9
Heparin Sodium MOCHIDA Anticoagulant agent 1.3 1.3 1.4
Beselna Therapeutic agent for condyloma acuminatum and actinic keratosis 1.0 1.0 1.0
Florid® Antimycotic drug 1.0 0.9 1.0
Urece Gout and hyperuricemia 2.2 0.2
Generic drugs 24.9 25.6 23.3
Skin Care Products 5.9 5.7 5.3